Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by investment analysts at Robert W. Baird from $67.00 to $132.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price objective suggests a potential upside of 66.60% from the stock’s current price.

Other research analysts have also issued reports about the stock. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Monday. Oppenheimer boosted their target price on shares of Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a research report on Monday. Wedbush raised their price objective on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Finally, HC Wainwright increased their price objective on Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a report on Monday. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $105.89.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $79.23 on Tuesday. The firm has a market cap of $3.42 billion, a PE ratio of -22.77 and a beta of 1.56. The firm’s fifty day moving average is $49.17 and its two-hundred day moving average is $41.17. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $84.86.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). The business had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. Research analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of DNTH. Caitong International Asset Management Co. Ltd bought a new stake in shares of Dianthus Therapeutics during the 4th quarter worth about $43,000. Seven Fleet Capital Management LP bought a new stake in Dianthus Therapeutics during the fourth quarter valued at about $604,000. Invesco Ltd. grew its position in shares of Dianthus Therapeutics by 125.9% in the fourth quarter. Invesco Ltd. now owns 101,489 shares of the company’s stock valued at $4,182,000 after purchasing an additional 56,560 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth about $550,000. Finally, Voloridge Investment Management LLC lifted its position in shares of Dianthus Therapeutics by 80.5% during the 4th quarter. Voloridge Investment Management LLC now owns 39,480 shares of the company’s stock worth $1,627,000 after purchasing an additional 17,612 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Key Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision for the Phase 3 CAPTIVATE CIDP trial — the company reported it met the Part A responder criteria (20 confirmed responders with fewer than 40 completers) and will keep the 300mg S.C. dose while engaging regulators to remove the 600mg dose, accelerating the program toward the planned next steps. Early GO Decision Press Release
• Positive Sentiment: Multiple analyst upgrades and higher price targets have lifted sentiment and helped push DNTH to a new 12‑month high; this analyst momentum supports further upside expectations. Analyst Upgrade / 12-Month High
• Neutral Sentiment: Company hosted / scheduled a conference call and webcast to discuss the interim responder analysis (transcript and slides available) — useful for investors seeking detail on responder definitions and next steps but not new data beyond the GO decision. Conference Call / Webcast Notice
• Neutral Sentiment: Short interest data reported appears negligible/zero and does not presently signal a material short pressure or squeeze dynamic. (Entry data showed 0 shares short, 0.0 days to cover.)
• Negative Sentiment: Proposed $400 million underwritten public offering — the company announced a sizable equity raise (with a 30‑day option to upsize by $60M), which can be dilutive and likely caps near‑term upside until proceeds are deployed. Public Offering Announcement
• Negative Sentiment: Q4 earnings miss — DNTH reported a larger-than-expected GAAP loss (EPS -$1.43 vs. consensus -$0.97); while revenue beat nominally, the wider loss underscores current cash burn and execution risks. Q4 Results / Earnings Miss
• Negative Sentiment: New AI/cyber/privacy risk disclosure — the company flagged heightened cyber, privacy and reputational risks related to AI integration, a cautionary corporate‑governance/regulatory risk that could increase compliance costs or negative headlines. AI / Cyber Risk Disclosure

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.